{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "from nltk import tokenize\n",
    "from operator import itemgetter\n",
    "import math\n",
    "from tqdm import tqdm\n",
    "import os\n",
    "import nltk\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import word_tokenize \n",
    "stop_words = set(stopwords.words('english'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['tdm1_metadf2.csv',\n",
       " 'genome wide association study_metadf2.csv',\n",
       " 'progression free survival_metadf2.csv',\n",
       " 'hormone therapy_metadf2.csv',\n",
       " 'overall survival_metadf2.csv',\n",
       " 'disease free survival_metadf2.csv',\n",
       " 'radiation_metadf2.csv',\n",
       " 'chemotherapy_metadf2.csv',\n",
       " 'neratinib_metadf2.csv',\n",
       " 'pertuzumab_metadf2.csv',\n",
       " 'pathologic complete response_metadf2.csv',\n",
       " 'surgery_metadf2.csv',\n",
       " 'polymorphism_metadf2.csv',\n",
       " 'neoadjuvant_metadf2.csv',\n",
       " 'adjuvant_metadf2.csv',\n",
       " 'trastuzumab_metadf2.csv',\n",
       " 'polygenic risk score_metadf2.csv',\n",
       " 'Breast Cancer_metadf2.csv']"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "kk = os.listdir(\"/home/amansinha/extractpubmed/papers/key_meta_all/\")\n",
    "kk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_keywords(doc, k):\n",
    "    total_words = doc.split()\n",
    "    total_word_length = len(total_words)\n",
    "    #print(total_word_length)\n",
    "    \n",
    "    total_sentences = tokenize.sent_tokenize(doc)\n",
    "    total_sent_len = len(total_sentences)\n",
    "    #print(total_sent_len)\n",
    "    \n",
    "    tf_score = {}\n",
    "    for each_word in total_words:\n",
    "        each_word = each_word.replace('.', '')\n",
    "        if each_word in tf_score:\n",
    "            tf_score[each_word] += 1\n",
    "        else:\n",
    "            tf_score[each_word] = 1\n",
    "            \n",
    "    tf_score.update((x, y/int(total_word_length)) for x,y in tf_score.items())\n",
    "    #print(tf_score)\n",
    "    \n",
    "    def check_sent(word, sentences): \n",
    "        final = [all([w in x for w in word]) for x in sentences] \n",
    "        sent_len = [sentences[i] for i in range(0, len(final)) if final[i]]\n",
    "        return int(len(sent_len))\n",
    "    \n",
    "    idf_score = {}\n",
    "    for each_word in total_words:\n",
    "        each_word = each_word.replace('.','')\n",
    "        if each_word not in stop_words:\n",
    "            if each_word in idf_score:\n",
    "                idf_score[each_word] = check_sent(each_word, total_sentences)\n",
    "            else:\n",
    "                idf_score[each_word] = 1\n",
    "\n",
    "    # Performing a log and divide\n",
    "    idf_score.update((x, math.log(int(total_sent_len)/y)) for x, y in idf_score.items())\n",
    "    #print(idf_score)\n",
    "    \n",
    "    tf_idf_score = {key: tf_score[key] * idf_score.get(key, 0) for key in tf_score.keys()}\n",
    "    #print(tf_idf_score)\n",
    "    \n",
    "    result = dict(sorted(tf_idf_score.items(), key = itemgetter(1), reverse = True)[:k]) \n",
    "    return result\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>title</th>\n",
       "      <th>keywords</th>\n",
       "      <th>publication_date</th>\n",
       "      <th>abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33479246</td>\n",
       "      <td>Fibroblast growth factor receptor facilitates ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2021-01-23</td>\n",
       "      <td>Trastuzumab-emtansine (T-DM1) is an antibody-d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>33259892</td>\n",
       "      <td>Third-line treatment of HER2-positive advanced...</td>\n",
       "      <td>['Breast cancer', 'HER2\\xa0+', 'Third line', '...</td>\n",
       "      <td>2020-12-02</td>\n",
       "      <td>Human epidermal growth factor receptor 2 posit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>33238772</td>\n",
       "      <td>Margetuximab for the treatment of HER2-positiv...</td>\n",
       "      <td>['Margetuximab', 'breast cancer', 'her2', 'mga...</td>\n",
       "      <td>2020-11-27</td>\n",
       "      <td>No specific standard treatment is currently re...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>32737515</td>\n",
       "      <td>Post-neoadjuvant treatment with capecitabine a...</td>\n",
       "      <td>['Breast cancer', 'Capecitabine', 'Radiochemot...</td>\n",
       "      <td>2020-08-02</td>\n",
       "      <td>Following neoadjuvant chemotherapy for breast ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>32236828</td>\n",
       "      <td>Comparison of outcomes in a population-based c...</td>\n",
       "      <td>['Cardiotoxicity', 'Heart failure', 'Overall s...</td>\n",
       "      <td>2020-04-03</td>\n",
       "      <td>Little data exist for comparing cardiac safety...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>32192389</td>\n",
       "      <td>Safety of trastuzumab after trastuzumab emtans...</td>\n",
       "      <td>['Breast cancer', 'HER2', 'nodular regenerativ...</td>\n",
       "      <td>2020-03-21</td>\n",
       "      <td>Trastuzumab emtansine is an antibody-drug conj...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>32104023</td>\n",
       "      <td>Analysis of the Cost-Effectiveness of Liquid B...</td>\n",
       "      <td>['biomarkers', 'breast cancer', 'cost-effectiv...</td>\n",
       "      <td>2020-02-28</td>\n",
       "      <td>Breast cancer is highly prevalent worldwide an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>31949426</td>\n",
       "      <td>Recent advances and optimal management of huma...</td>\n",
       "      <td>['Breast cancer', 'TDM1', 'neratinib', 'pertuz...</td>\n",
       "      <td>2020-01-18</td>\n",
       "      <td>With the introduction of anthracycline-based r...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>31781874</td>\n",
       "      <td>When to Add Additional Anti-HER2 Therapy to Ad...</td>\n",
       "      <td>['Adjuvant', 'Early', 'HER2', 'Neoadjuvant', '...</td>\n",
       "      <td>2019-11-30</td>\n",
       "      <td>One year of trastuzumab dramatically improves ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>31449983</td>\n",
       "      <td>The evolving role of trastuzumab emtansine (T-...</td>\n",
       "      <td>['Brain metastases', 'Breast cancer', 'HER2', ...</td>\n",
       "      <td>2019-08-27</td>\n",
       "      <td>Approximately 30-50% of advanced human epiderm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>31230485</td>\n",
       "      <td>Investigational drugs in early stage clinical ...</td>\n",
       "      <td>['ADCs', 'HER2+ breast cancer', 'TKIs', 'bispe...</td>\n",
       "      <td>2019-06-25</td>\n",
       "      <td>Despite improvements in the management of HER2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>30957209</td>\n",
       "      <td>Systemic Therapy of Central Nervous System Met...</td>\n",
       "      <td>['Brain metastases', 'Breast cancer', 'Chemoth...</td>\n",
       "      <td>2019-04-09</td>\n",
       "      <td>Historically, systemic treatment options for p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>30833989</td>\n",
       "      <td>Post-neoadjuvant treatment and the management ...</td>\n",
       "      <td>['breast cancer', 'chemotherapy', 'pathologic ...</td>\n",
       "      <td>2019-03-06</td>\n",
       "      <td>Achieving a pathologic complete response after...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>30595754</td>\n",
       "      <td>ASCO 2018: highlights in HER2-positive metasta...</td>\n",
       "      <td>['ASCO Annual Meeting 2018', 'HER2-positive di...</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>At the 2018 ASCO Annual Meeting, data from sev...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>30560092</td>\n",
       "      <td>Exceptional and Durable Responses to TDM-1 Aft...</td>\n",
       "      <td>['T-DM1', 'adotrastuzumab', 'emtansine', 'immu...</td>\n",
       "      <td>2018-12-19</td>\n",
       "      <td>Breast Cancer (BC) skin metastases represent a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>30159132</td>\n",
       "      <td>Dual targeting of HER2-positive breast cancer ...</td>\n",
       "      <td>['HER2', 'TDM1', 'breast cancer', 'pertuzumab'...</td>\n",
       "      <td>2018-08-31</td>\n",
       "      <td>Targeting of HER2-positive tumors with trastuz...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>30087853</td>\n",
       "      <td>Trastuzumab Emtansine for the Treatment of HER...</td>\n",
       "      <td>['brain metastases', 'carcinoma ex-pleomorphic...</td>\n",
       "      <td>2018-08-09</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>29721483</td>\n",
       "      <td>Practical consensus recommendations regarding ...</td>\n",
       "      <td>['Capecitabine', 'TDM1', 'combination systemic...</td>\n",
       "      <td>2018-05-04</td>\n",
       "      <td>Metastatic breast cancer (MBC) is cancer that ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>29721477</td>\n",
       "      <td>Practical consensus recommendations on Her2 +v...</td>\n",
       "      <td>['Herceptin', 'TDM1', 'WBCR', 'stereotactic ra...</td>\n",
       "      <td>2018-05-04</td>\n",
       "      <td>Breast cancer is a common cause of brain metas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>29719406</td>\n",
       "      <td>Cardiotoxic effects of the novel approved anti...</td>\n",
       "      <td>['breast cancer', 'immunotherapy', 'pertuzumab...</td>\n",
       "      <td>2018-05-03</td>\n",
       "      <td>Pertuzumab, a novel anti-epidermal growth fact...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>29679630</td>\n",
       "      <td>High irisin levels are associated with better ...</td>\n",
       "      <td>['Bone remodeling', 'Irisin', 'Multiple daily ...</td>\n",
       "      <td>2018-04-22</td>\n",
       "      <td>Irisin is a new peptide produced mainly by the...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>29215678</td>\n",
       "      <td>Decrease in Mandibular Cortical in Patients Wi...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2017-12-08</td>\n",
       "      <td>In this study we analyzed the mandibular corti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>27995546</td>\n",
       "      <td>Preliminary experience of the concurrent use o...</td>\n",
       "      <td>['Brain metastases', 'Concurrent treatment', '...</td>\n",
       "      <td>2016-12-21</td>\n",
       "      <td>This is preliminary study assessing the effica...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>27843589</td>\n",
       "      <td>Highlights from the San Antonio Breast Cancer ...</td>\n",
       "      <td>['Breast Cancer']</td>\n",
       "      <td>2016-11-16</td>\n",
       "      <td>A critical review on the practice changing stu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>27342941</td>\n",
       "      <td>Preliminary results of the concurrent use of r...</td>\n",
       "      <td>['Concurrent treatment', 'Metastatic breast ca...</td>\n",
       "      <td>2016-06-28</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>27338847</td>\n",
       "      <td>Human epidermal growth factor antagonists and ...</td>\n",
       "      <td>['Ado-trastuzumab (T-DM1)', 'Human epidermal r...</td>\n",
       "      <td>2016-06-25</td>\n",
       "      <td>The Human Epidermal growth factor Receptor 2 (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27132096</td>\n",
       "      <td>Effects of DGAT1 K232A polymorphism and milkin...</td>\n",
       "      <td>['DGAT1', 'dairy cow', 'milk composition', 'on...</td>\n",
       "      <td>2016-05-02</td>\n",
       "      <td>Milk spontaneous lipolysis (SL) of milk trigly...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>27114895</td>\n",
       "      <td>ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HE...</td>\n",
       "      <td>['Adotrastuzumab', 'Brain Metastasis', 'Breast...</td>\n",
       "      <td>2016-04-27</td>\n",
       "      <td>The incidence of breast cancer brain metastasi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>26871453</td>\n",
       "      <td>TDM1 Regulation Determines the Number of Meiot...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2016-02-13</td>\n",
       "      <td>Cell cycle control must be modified at meiosis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>26859680</td>\n",
       "      <td>Marked enhancement of lysosomal targeting and ...</td>\n",
       "      <td>['ErbB2', 'HSP90', 'Trastuzumab', 'breast canc...</td>\n",
       "      <td>2016-02-10</td>\n",
       "      <td>Targeted delivery of anticancer drugs to tumor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>26557884</td>\n",
       "      <td>Safety and efficacy of the combination of T-DM...</td>\n",
       "      <td>['HER2-positive', 'TDM1', 'breast cancer', 'ra...</td>\n",
       "      <td>2015-11-12</td>\n",
       "      <td>Approximately 35% of patients with confirmed H...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>26348709</td>\n",
       "      <td>The Chromatin Protein DUET/MMD1 Controls Expre...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2015-09-09</td>\n",
       "      <td>Meiosis produces haploid cells essential for s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>26276735</td>\n",
       "      <td>Mechanisms of lapatinib resistance in HER2-dri...</td>\n",
       "      <td>['Breast cancer', 'ErbB2/HER2', 'Lapatinib', '...</td>\n",
       "      <td>2015-08-16</td>\n",
       "      <td>Targeted therapies have been approved for vari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>25908069</td>\n",
       "      <td>Long-term prognosis in patients with type 1 an...</td>\n",
       "      <td>['isolated CABG', 'major adverse coronary even...</td>\n",
       "      <td>2015-04-25</td>\n",
       "      <td>Patients with diabetes mellitus (DM) have an i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>25937839</td>\n",
       "      <td>Insulin resistance and associated factors in p...</td>\n",
       "      <td>['Estimated glucose disposal rate formula', 'I...</td>\n",
       "      <td>2014-01-01</td>\n",
       "      <td>To assess the presence of insulin resistance (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>22844260</td>\n",
       "      <td>OSD1 promotes meiotic progression via APC/C in...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2012-07-31</td>\n",
       "      <td>Cell cycle control is modified at meiosis comp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>22749531</td>\n",
       "      <td>Costs of treatment and complications of adult ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2012-07-04</td>\n",
       "      <td>Costs associated with diabetes represent a lar...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>21119056</td>\n",
       "      <td>Meiotic progression in Arabidopsis is governed...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2010-12-02</td>\n",
       "      <td>Meiosis is a modified cell division that produ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>20877670</td>\n",
       "      <td>Immunological Approaches in the Treatment of M...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2009-01-01</td>\n",
       "      <td>A better understanding of tumor biology has le...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>20578412</td>\n",
       "      <td>Thyroid autoimmunity and type 1 diabetes in ch...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2009-01-01</td>\n",
       "      <td>The incidence of autoimmune thyroiditis in pat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>2442724</td>\n",
       "      <td>A labile inhibitor blocks endo A gene transcri...</td>\n",
       "      <td>[]</td>\n",
       "      <td>1987-08-11</td>\n",
       "      <td>The endo A gene encoding for an intermediate f...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>16347085</td>\n",
       "      <td>Conjugal Transfer of Bacteriophage Resistance ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>1986-06-01</td>\n",
       "      <td>Agar surface conjugal matings were used to int...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>7158680</td>\n",
       "      <td>The significance of natural killer activity in...</td>\n",
       "      <td>[]</td>\n",
       "      <td>1982-12-01</td>\n",
       "      <td>A number of mouse strains of known F9 resistan...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    pubmed_id                                              title  \\\n",
       "0    33479246  Fibroblast growth factor receptor facilitates ...   \n",
       "1    33259892  Third-line treatment of HER2-positive advanced...   \n",
       "2    33238772  Margetuximab for the treatment of HER2-positiv...   \n",
       "3    32737515  Post-neoadjuvant treatment with capecitabine a...   \n",
       "4    32236828  Comparison of outcomes in a population-based c...   \n",
       "5    32192389  Safety of trastuzumab after trastuzumab emtans...   \n",
       "6    32104023  Analysis of the Cost-Effectiveness of Liquid B...   \n",
       "7    31949426  Recent advances and optimal management of huma...   \n",
       "8    31781874  When to Add Additional Anti-HER2 Therapy to Ad...   \n",
       "9    31449983  The evolving role of trastuzumab emtansine (T-...   \n",
       "10   31230485  Investigational drugs in early stage clinical ...   \n",
       "11   30957209  Systemic Therapy of Central Nervous System Met...   \n",
       "12   30833989  Post-neoadjuvant treatment and the management ...   \n",
       "13   30595754  ASCO 2018: highlights in HER2-positive metasta...   \n",
       "14   30560092  Exceptional and Durable Responses to TDM-1 Aft...   \n",
       "15   30159132  Dual targeting of HER2-positive breast cancer ...   \n",
       "16   30087853  Trastuzumab Emtansine for the Treatment of HER...   \n",
       "17   29721483  Practical consensus recommendations regarding ...   \n",
       "18   29721477  Practical consensus recommendations on Her2 +v...   \n",
       "19   29719406  Cardiotoxic effects of the novel approved anti...   \n",
       "20   29679630  High irisin levels are associated with better ...   \n",
       "21   29215678  Decrease in Mandibular Cortical in Patients Wi...   \n",
       "22   27995546  Preliminary experience of the concurrent use o...   \n",
       "23   27843589  Highlights from the San Antonio Breast Cancer ...   \n",
       "24   27342941  Preliminary results of the concurrent use of r...   \n",
       "25   27338847  Human epidermal growth factor antagonists and ...   \n",
       "26   27132096  Effects of DGAT1 K232A polymorphism and milkin...   \n",
       "27   27114895  ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HE...   \n",
       "28   26871453  TDM1 Regulation Determines the Number of Meiot...   \n",
       "29   26859680  Marked enhancement of lysosomal targeting and ...   \n",
       "30   26557884  Safety and efficacy of the combination of T-DM...   \n",
       "31   26348709  The Chromatin Protein DUET/MMD1 Controls Expre...   \n",
       "32   26276735  Mechanisms of lapatinib resistance in HER2-dri...   \n",
       "33   25908069  Long-term prognosis in patients with type 1 an...   \n",
       "34   25937839  Insulin resistance and associated factors in p...   \n",
       "35   22844260  OSD1 promotes meiotic progression via APC/C in...   \n",
       "36   22749531  Costs of treatment and complications of adult ...   \n",
       "37   21119056  Meiotic progression in Arabidopsis is governed...   \n",
       "38   20877670  Immunological Approaches in the Treatment of M...   \n",
       "39   20578412  Thyroid autoimmunity and type 1 diabetes in ch...   \n",
       "40    2442724  A labile inhibitor blocks endo A gene transcri...   \n",
       "41   16347085  Conjugal Transfer of Bacteriophage Resistance ...   \n",
       "42    7158680  The significance of natural killer activity in...   \n",
       "\n",
       "                                             keywords publication_date  \\\n",
       "0                                                  []       2021-01-23   \n",
       "1   ['Breast cancer', 'HER2\\xa0+', 'Third line', '...       2020-12-02   \n",
       "2   ['Margetuximab', 'breast cancer', 'her2', 'mga...       2020-11-27   \n",
       "3   ['Breast cancer', 'Capecitabine', 'Radiochemot...       2020-08-02   \n",
       "4   ['Cardiotoxicity', 'Heart failure', 'Overall s...       2020-04-03   \n",
       "5   ['Breast cancer', 'HER2', 'nodular regenerativ...       2020-03-21   \n",
       "6   ['biomarkers', 'breast cancer', 'cost-effectiv...       2020-02-28   \n",
       "7   ['Breast cancer', 'TDM1', 'neratinib', 'pertuz...       2020-01-18   \n",
       "8   ['Adjuvant', 'Early', 'HER2', 'Neoadjuvant', '...       2019-11-30   \n",
       "9   ['Brain metastases', 'Breast cancer', 'HER2', ...       2019-08-27   \n",
       "10  ['ADCs', 'HER2+ breast cancer', 'TKIs', 'bispe...       2019-06-25   \n",
       "11  ['Brain metastases', 'Breast cancer', 'Chemoth...       2019-04-09   \n",
       "12  ['breast cancer', 'chemotherapy', 'pathologic ...       2019-03-06   \n",
       "13  ['ASCO Annual Meeting 2018', 'HER2-positive di...       2019-01-01   \n",
       "14  ['T-DM1', 'adotrastuzumab', 'emtansine', 'immu...       2018-12-19   \n",
       "15  ['HER2', 'TDM1', 'breast cancer', 'pertuzumab'...       2018-08-31   \n",
       "16  ['brain metastases', 'carcinoma ex-pleomorphic...       2018-08-09   \n",
       "17  ['Capecitabine', 'TDM1', 'combination systemic...       2018-05-04   \n",
       "18  ['Herceptin', 'TDM1', 'WBCR', 'stereotactic ra...       2018-05-04   \n",
       "19  ['breast cancer', 'immunotherapy', 'pertuzumab...       2018-05-03   \n",
       "20  ['Bone remodeling', 'Irisin', 'Multiple daily ...       2018-04-22   \n",
       "21                                                 []       2017-12-08   \n",
       "22  ['Brain metastases', 'Concurrent treatment', '...       2016-12-21   \n",
       "23                                  ['Breast Cancer']       2016-11-16   \n",
       "24  ['Concurrent treatment', 'Metastatic breast ca...       2016-06-28   \n",
       "25  ['Ado-trastuzumab (T-DM1)', 'Human epidermal r...       2016-06-25   \n",
       "26  ['DGAT1', 'dairy cow', 'milk composition', 'on...       2016-05-02   \n",
       "27  ['Adotrastuzumab', 'Brain Metastasis', 'Breast...       2016-04-27   \n",
       "28                                                 []       2016-02-13   \n",
       "29  ['ErbB2', 'HSP90', 'Trastuzumab', 'breast canc...       2016-02-10   \n",
       "30  ['HER2-positive', 'TDM1', 'breast cancer', 'ra...       2015-11-12   \n",
       "31                                                 []       2015-09-09   \n",
       "32  ['Breast cancer', 'ErbB2/HER2', 'Lapatinib', '...       2015-08-16   \n",
       "33  ['isolated CABG', 'major adverse coronary even...       2015-04-25   \n",
       "34  ['Estimated glucose disposal rate formula', 'I...       2014-01-01   \n",
       "35                                                 []       2012-07-31   \n",
       "36                                                 []       2012-07-04   \n",
       "37                                                 []       2010-12-02   \n",
       "38                                                 []       2009-01-01   \n",
       "39                                                 []       2009-01-01   \n",
       "40                                                 []       1987-08-11   \n",
       "41                                                 []       1986-06-01   \n",
       "42                                                 []       1982-12-01   \n",
       "\n",
       "                                             abstract  \n",
       "0   Trastuzumab-emtansine (T-DM1) is an antibody-d...  \n",
       "1   Human epidermal growth factor receptor 2 posit...  \n",
       "2   No specific standard treatment is currently re...  \n",
       "3   Following neoadjuvant chemotherapy for breast ...  \n",
       "4   Little data exist for comparing cardiac safety...  \n",
       "5   Trastuzumab emtansine is an antibody-drug conj...  \n",
       "6   Breast cancer is highly prevalent worldwide an...  \n",
       "7   With the introduction of anthracycline-based r...  \n",
       "8   One year of trastuzumab dramatically improves ...  \n",
       "9   Approximately 30-50% of advanced human epiderm...  \n",
       "10  Despite improvements in the management of HER2...  \n",
       "11  Historically, systemic treatment options for p...  \n",
       "12  Achieving a pathologic complete response after...  \n",
       "13  At the 2018 ASCO Annual Meeting, data from sev...  \n",
       "14  Breast Cancer (BC) skin metastases represent a...  \n",
       "15  Targeting of HER2-positive tumors with trastuz...  \n",
       "16                                                NaN  \n",
       "17  Metastatic breast cancer (MBC) is cancer that ...  \n",
       "18  Breast cancer is a common cause of brain metas...  \n",
       "19  Pertuzumab, a novel anti-epidermal growth fact...  \n",
       "20  Irisin is a new peptide produced mainly by the...  \n",
       "21  In this study we analyzed the mandibular corti...  \n",
       "22  This is preliminary study assessing the effica...  \n",
       "23  A critical review on the practice changing stu...  \n",
       "24                                                NaN  \n",
       "25  The Human Epidermal growth factor Receptor 2 (...  \n",
       "26  Milk spontaneous lipolysis (SL) of milk trigly...  \n",
       "27  The incidence of breast cancer brain metastasi...  \n",
       "28  Cell cycle control must be modified at meiosis...  \n",
       "29  Targeted delivery of anticancer drugs to tumor...  \n",
       "30  Approximately 35% of patients with confirmed H...  \n",
       "31  Meiosis produces haploid cells essential for s...  \n",
       "32  Targeted therapies have been approved for vari...  \n",
       "33  Patients with diabetes mellitus (DM) have an i...  \n",
       "34  To assess the presence of insulin resistance (...  \n",
       "35  Cell cycle control is modified at meiosis comp...  \n",
       "36  Costs associated with diabetes represent a lar...  \n",
       "37  Meiosis is a modified cell division that produ...  \n",
       "38  A better understanding of tumor biology has le...  \n",
       "39  The incidence of autoimmune thyroiditis in pat...  \n",
       "40  The endo A gene encoding for an intermediate f...  \n",
       "41  Agar surface conjugal matings were used to int...  \n",
       "42  A number of mouse strains of known F9 resistan...  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('/home/amansinha/extractpubmed/papers/key_meta_all/tdm1_metadf2.csv')\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "43it [00:12,  3.39it/s]\n",
      "43it [00:12,  3.42it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For tdm1: title are 0.5385959153340232 and abstract are 0.5577921007718477\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "5000it [27:17,  3.05it/s]\n",
      "4629it [24:48,  3.11it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "4629 authorkeys: {'cholesky decomposition', 'multiphenotype analysis', 'genome-wide association study', 'kinship matrix', 'linear mixed models'} \n",
      "manualkeys: set() \n",
      "\n",
      "ISSUE: \n",
      "                    \n",
      "For genome wide association study: title are nan and abstract are 0.557202183806945\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "4998it [1:04:46,  1.29it/s]\n",
      "4998it [35:33,  2.34it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For progression free survival: title are nan and abstract are nan\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "4987it [29:58,  2.77it/s]\n",
      "4987it [29:30,  2.82it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For hormone therapy: title are nan and abstract are nan\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "4969it [1:11:55,  1.15it/s] \n",
      "4969it [37:06,  2.23it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For overall survival: title are nan and abstract are nan\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "4994it [35:12,  2.36it/s]\n",
      "4994it [37:00,  2.25it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "For disease free survival: title are 0.5395895697418176 and abstract are 0.5458312823270379\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "4505it [33:23,  2.25it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "4505 authorkeys: {'thermoluminescence', 'phosphor', 'medical dosimetry', 'neutron', 'tld'} \n",
      "manualkeys: {'of', 'cr-39', 'and', 'to', 'tld-600/tld-700', 'for', 'neutrons', 'dosimetry', 'medical', 'response'} \n",
      "\n",
      "ISSUE: Response of TLD-600/TLD-700 and CR-39 to neutrons for medical dosimetry.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "7it [00:03,  2.16it/s]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "7 authorkeys: {'trauma', 'pediatric', 'radiation exposure'} \n",
      "manualkeys: {'stay,', 'exposure', '(or', 'ct', '0001)', 'icu', '95%', 'p<', 'iss', '15'} \n",
      "\n",
      "ISSUE: The optimal imaging strategy in hemodynamically stable pediatric blunt trauma remains to be defined. The purpose of this study was to determine the differences between selective and liberal computed tomography (CT) strategy in a pediatric trauma population with respect to radiation exposure and outcomes.\n",
      "We performed a retrospective analysis of hemodynamically stable blunt pediatric trauma patients (≤16 y) who were admitted to a Level I trauma center between 2013-2016. Patients were stratified into selective and liberal imaging cohorts. Univariate and multivariate regression analyses were used to compare outcomes between the groups. Outcomes included radiation dose, hospital and ICU length of stay, complications and mortality.\n",
      "Of the 485 patients included, 176 underwent liberal and 309 selective CT imaging. The liberal cohort were more likely to be severely injured (ISS>15: 34.1 versus 8.4%, P< 0.001). The odds of exposure to a radiation dose of >15 mSv were higher with liberal scanning in patients with both ISS > 15 (OR 2.78, 95% CI 1.76-5.19, P< 0.001) and ISS ≤ 15 (OR 3.41, 95% CI 2.19-8.44, P < 0.001). Adjusted outcomes regarding mortality, ICU length of stay, and complications were similar between the cohorts.\n",
      "Selective CT imaging in hemodynamically stable blunt pediatric trauma patients was associated with reduced radiation exposure and similar outcomes when compared to a liberal CT strategy.\n",
      "For radiation: title are nan and abstract are 0.5790417550456903\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "3it [00:00,  4.46it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3 authorkeys: {'photo-dynamic therapy (pdt)', 'ciprofloxacin', '5-amino levulinic acid', 'iron chelator', '5-ala', 'chordoma'} \n",
      "manualkeys: {'of', 'mediated', 'ciprofloxacin', 'enhances', 'acid', 'for', 'photodynamic', '5-aminolevulinic', 'phototoxicity', 'treatment'} \n",
      "\n",
      "ISSUE: Ciprofloxacin enhances phototoxicity of 5-aminolevulinic acid mediated photodynamic treatment for chordoma cell lines.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "3it [00:01,  2.46it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3 authorkeys: {'photo-dynamic therapy (pdt)', 'ciprofloxacin', '5-amino levulinic acid', 'iron chelator', '5-ala', 'chordoma'} \n",
      "manualkeys: {'h)', '(15', '50', 'incubation', 'pdt', 'in', '(4', '5-ala', 'chordoma', '6'} \n",
      "\n",
      "ISSUE: Chordoma are uncommon aggressive tumors of the skeleton. Surgical resection is often subtotal and adjuvant treatment possibilities are limited as chordomas are highly chemo- and radioresistant. In the present study we examined the impact of 5-ALA PDT on different human chordoma cell lines. Furthermore, we investigated the variation of two parameters: (1.) 5-ALA incubation time and (2.) supplemental use of ciprofloxacin as iron chelator.\n",
      "Experiments were realized in vitro with three different human chordoma cell lines: U-CH2, U-CH2B and U-CH14. After pre-incubation for 24 h with various concentrations of ciprofloxacin (1.5 - 5.0 μg/ml), different amounts of 5-ALA (15 - 50 μg/ml) were applied to the cells either for a brief (4 h) or a long (6 h) incubation time. Subsequently cells were exposed to photodynamic radiation. Cell viability was exploited by WST-1 assay. Thus, for each of the three cell lines, two drug combinations (ciprofloxacin plus 5-ALA and 5-ALA only) and two incubation times (short, 4 h and long, 6 h) were tested. Negative control groups were also examined.\n",
      "Supplemental use of ciprofloxacin led to increased cell death in each of the cell lines. Different 5-ALA incubation times (4 h vs. 6 h) showed no significant differences in cell viability except for U-CH2.\n",
      "Ciprofloxacin as an ordinary applied antibiotic, enhanced the effect of 5-ALA PDT on different human chordoma cell lines in vitro. The impact was dependent on the dose of ciprofloxacin-5-ALA. There were no notable differences for the tested 5-ALA incubation times. In human chordoma cell lines 5-ALA PDT may effectively be amended by ciprofloxacin.\n",
      "For chemotherapy: title are 0.5475997383395831 and abstract are 0.5801537349820137\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "8it [00:04,  1.99it/s]\n",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "8 authorkeys: {'trastuzumab deruxtecan', 'tucatinib', 'trastuzumab-emtansine', 'lapatinib', 'neratinib', 'trastuzumab', 'brain metastases', 'her2-positive breast cancer'} \n",
      "manualkeys: {'current', 'cancer', 'options', 'breast', 'her2-positive', 'with', 'for', 'brain', 'patients', 'treatment'} \n",
      "\n",
      "ISSUE: Current treatment options for HER2-positive breast cancer patients with brain metastases.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "0it [00:00, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 authorkeys: {'human epidermal growth factor receptor 2', 'breast neoplasms', 'neratinib', 'hormone receptor'} \n",
      "manualkeys: {'human', 'receptor', 'factor', 'growth', 'epidermal', '(hr),', 'pi3k/akt/mtor', 'receptor-2(her-2)', 'highly', 'hormone'} \n",
      "\n",
      "ISSUE: Hormone receptor (HR), human epidermal growth factor receptor-2(HER-2) double positive breast cancer is a highly aggressive disease, and it is more susceptible to drug resistance and metastasis. Currently, although anti-HER-2 monoclonal antibody combined with endocrine therapy is commonly used in clinical practice, patients with HR-positive and HER-2-positive still have a poor prognosis. That may be caused by the activation of downstream PI3K/Akt/mTOR signaling pathway of HER-2. Therefore, simultaneously blocking the extracellular, intracellular and downstream PI3K/Akt/mTOR signaling pathway of HER-2, as well as the dual blockade of HER-2 and HR, is more conducive to the treatment of HR positive and HER-2 positive breast cancer. The small-molecule tyrosine kinase inhibitor neratinib not only inhibits the phosphorylation of HER-1, HER-2 and HER-4, but also blocks the downstream signal transduction of PI3K/Akt and Ras/Raf/MEK/ERK pathways. The intensive adjuvant chemotherapy studies has confirmed that nelatinib can improve the prognosis of patients with HER-2 positive breast cancer, especially those with HR and HER-2 double positive patients. Nelatinib has also achieved positive effect on the treatment of advanced breast cancer, but relevant data on the treatment of HR-positive and HER-2 positive advanced breast cancer are still lacking. Lapatinib, a small-molecule HER inhibitor similar to neratinib, has shown some effects on the treatment of HR-positive and HER-2 positive patients with advanced breast cancer. Given that nelatinib has a superior efficacy than lapatinib, it is expected to provide more ideas and options for the treatment strategies of breast cancer.\n",
      "激素受体(HR)阳性人表皮生长因子受体2(HER-2)阳性乳腺癌侵袭性强，易发生耐药而复发转移，目前临床多采用抗HER-2单抗联合内分泌治疗。但即使两药联合治疗，患者的预后仍不理想，这可能是HER-2下游的PI3K/Akt/mTOR信号通路激活所导致，因此HER-2受体胞外、胞内及其下游PI3K/Akt/mTOR信号通路多重抑制，及HER-2和HR的双重阻断，更有利于HR阳性HER-2阳性乳腺癌的治疗。小分子酪氨酸激酶抑制剂奈拉替尼不仅能抑制HER-1、HER-2和HER-4受体磷酸化，还可以阻断PI3K/Akt和Ras/Raf/MEK/ERK途径的下游信号传导。在强化辅助治疗研究中已证实，奈拉替尼可改善HER-2阳性乳腺癌患者的预后，尤其HR阳性HER-2阳性患者获益更加显著。在晚期乳腺癌的治疗中奈拉替尼也获得了肯定疗效，但尚缺乏奈拉替尼治疗HR阳性HER-2阳性晚期乳腺癌的相关数据。与奈拉替尼类似的小分子HER抑制剂拉帕替尼，在HR阳性HER-2阳性晚期乳腺癌患者的治疗中显示出一定疗效。鉴于奈拉替尼较拉帕替尼更优的作用机制，其有望为乳腺癌的治疗提供更多思路和选择。.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "ename": "ZeroDivisionError",
     "evalue": "division by zero",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mZeroDivisionError\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-53-af2b716d2495>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     36\u001b[0m             \u001b[0;31m#if c == 100: break\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     37\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 38\u001b[0;31m         \u001b[0mta1\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msum\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mscores1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m/\u001b[0m\u001b[0mc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     39\u001b[0m         \u001b[0mta2\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msum\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mscores2\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m/\u001b[0m\u001b[0mc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     40\u001b[0m         \u001b[0mta3\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msum\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mscores3\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m/\u001b[0m\u001b[0mc\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mZeroDivisionError\u001b[0m: division by zero"
     ]
    }
   ],
   "source": [
    "tn, tt1, tt2, tt3, tabst1, tabst2,tabst3, tc = [],[],[],[], [], [], [], []\n",
    "c = 0\n",
    "for k in kk:\n",
    "    \n",
    "    df = pd.read_csv(f'/home/amansinha/extractpubmed/papers/key_meta_all/{k}')\n",
    "    df['keywords'] = df['keywords'].str.strip('[]').str.split(',')\n",
    "    df['keywords'] = df['keywords'].apply(lambda x: [xx.strip().strip(\"''\") for xx in x])\n",
    "    \n",
    "    \n",
    "    name = k.split('_')[0]\n",
    "\n",
    "    ta1, ta2, ta3 = [], [], []\n",
    "    \n",
    "    for t in ['title', 'abstract']:\n",
    "        c= 0\n",
    "        scores1, scores2, scores3 = [], [],[]\n",
    "        for i, (key, abst) in tqdm(enumerate(zip(df['keywords'], df[t]))):\n",
    "            try:\n",
    "                #print((key))\n",
    "                if len(key)>1  and (not pd.isna(abst)):\n",
    "                    keylist = set(list(map(str.lower, key)))\n",
    "                    manual_keylist = set(list(map(str.lower, get_keywords(abst, 10).keys() )))\n",
    "                    s1 = simple_match(keylist, manual_keylist)\n",
    "                    s2 = substring_match(keylist, manual_keylist)\n",
    "                    s3 = semantic_match(keylist, manual_keylist, tokenizer, model)\n",
    "                    \n",
    "                    #print(i, 'authorkeys:',keylist,'\\nmanualkeys:',manual_keylist, '\\n')\n",
    "                    scores1.append(s1)\n",
    "                    scores2.append(s2)\n",
    "                    scores3.append(s3)\n",
    "                    c +=1\n",
    "            except:\n",
    "                print(i, 'authorkeys:',keylist,'\\nmanualkeys:',manual_keylist, '\\n')\n",
    "                print('ISSUE:', abst)\n",
    "                break\n",
    "            #if c == 100: break\n",
    "                \n",
    "        ta1.append(sum(scores1)/c)\n",
    "        ta2.append(sum(scores2)/c)\n",
    "        ta3.append(sum(scores3)/c)\n",
    "        #print('*'*50)\n",
    "        \n",
    "        \n",
    "    \n",
    "    print(f'For {name}: title are {ta3[0]} and abstract are {ta3[1]}')\n",
    "    tn.append(name); tt1.append(ta1[0]);tt2.append(ta2[0]); tt3.append(ta3[0]); \\\n",
    "    tabst1.append(ta1[1]); tabst2.append(ta2[1]);tabst3.append(ta3[1]); tc.append(c)\n",
    "    #break\n",
    "    #result.append({'key':name,'keywordVtitle_b': ta1[0], 'keywordVtitle_sbs': ta2[0], 'keywordVabstract_b': ta1[1],'keywordVabstract_sbs': ta2[1]}, ignore_index=True)\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "result = pd.DataFrame(columns = ['key', 'keywordVtitle_b','keywordVtitle_sbs', 'keywordVtitle_sem', 'keywordVabstract_b','keywordVabstract_sbs', 'keywordVabstract_sem', 'nsamples'])\n",
    "result['key']  = tn\n",
    "result['keywordVtitle_b'] = tt1\n",
    "result['keywordVtitle_sbs'] = tt2\n",
    "result['keywordVtitle_sem'] = tt3\n",
    "result['keywordVabstract_b'] = tabst1\n",
    "result['keywordVabstract_sbs'] = tabst2\n",
    "result['keywordVabstract_sem'] = tabst3\n",
    "result['nsamples'] = tc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>key</th>\n",
       "      <th>keywordVtitle_b</th>\n",
       "      <th>keywordVtitle_sbs</th>\n",
       "      <th>keywordVtitle_sem</th>\n",
       "      <th>keywordVabstract_b</th>\n",
       "      <th>keywordVabstract_sbs</th>\n",
       "      <th>keywordVabstract_sem</th>\n",
       "      <th>nsamples</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>tdm1</td>\n",
       "      <td>0.112037</td>\n",
       "      <td>0.669167</td>\n",
       "      <td>0.538596</td>\n",
       "      <td>0.055952</td>\n",
       "      <td>0.377976</td>\n",
       "      <td>0.557792</td>\n",
       "      <td>28</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>genome wide association study</td>\n",
       "      <td>0.071084</td>\n",
       "      <td>0.761368</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.045866</td>\n",
       "      <td>0.356892</td>\n",
       "      <td>0.557202</td>\n",
       "      <td>2944</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>progression free survival</td>\n",
       "      <td>0.120741</td>\n",
       "      <td>0.882582</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.067391</td>\n",
       "      <td>0.445179</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3607</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>hormone therapy</td>\n",
       "      <td>0.103923</td>\n",
       "      <td>0.853283</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.059205</td>\n",
       "      <td>0.378839</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3280</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>overall survival</td>\n",
       "      <td>0.107009</td>\n",
       "      <td>0.880749</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.062405</td>\n",
       "      <td>0.399481</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3557</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>disease free survival</td>\n",
       "      <td>0.101470</td>\n",
       "      <td>0.926997</td>\n",
       "      <td>0.539590</td>\n",
       "      <td>0.055107</td>\n",
       "      <td>0.442631</td>\n",
       "      <td>0.545831</td>\n",
       "      <td>3551</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>radiation</td>\n",
       "      <td>0.088845</td>\n",
       "      <td>0.881257</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.057143</td>\n",
       "      <td>0.579042</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>chemotherapy</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.833333</td>\n",
       "      <td>0.547600</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.580154</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                             key  keywordVtitle_b  keywordVtitle_sbs  \\\n",
       "0                           tdm1         0.112037           0.669167   \n",
       "1  genome wide association study         0.071084           0.761368   \n",
       "2      progression free survival         0.120741           0.882582   \n",
       "3                hormone therapy         0.103923           0.853283   \n",
       "4               overall survival         0.107009           0.880749   \n",
       "5          disease free survival         0.101470           0.926997   \n",
       "6                      radiation         0.088845           0.881257   \n",
       "7                   chemotherapy         0.000000           0.833333   \n",
       "\n",
       "   keywordVtitle_sem  keywordVabstract_b  keywordVabstract_sbs  \\\n",
       "0           0.538596            0.055952              0.377976   \n",
       "1                NaN            0.045866              0.356892   \n",
       "2                NaN            0.067391              0.445179   \n",
       "3                NaN            0.059205              0.378839   \n",
       "4                NaN            0.062405              0.399481   \n",
       "5           0.539590            0.055107              0.442631   \n",
       "6                NaN            0.000000              0.057143   \n",
       "7           0.547600            0.166667              0.166667   \n",
       "\n",
       "   keywordVabstract_sem  nsamples  \n",
       "0              0.557792        28  \n",
       "1              0.557202      2944  \n",
       "2                   NaN      3607  \n",
       "3                   NaN      3280  \n",
       "4                   NaN      3557  \n",
       "5              0.545831      3551  \n",
       "6              0.579042         5  \n",
       "7              0.580154         1  "
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Correlation is defined the average of count of intersection of number of keywords between the actual keywords provided by the authors over complete number of samples."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "authorkeys= {'t‑dm1', 'radiochemotherapy', 'radiotherapy', 'capecitabine', 'breast cancer'} \n",
    "manualkeys= {'with', 'emtansine', 'and', 'trastuzumab', 'post-neoadjuvant', 'treatment', 'in', 'breast', 'cancer', 'capecitabine'}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "def simple_match(authorkeys, manualkeys):\n",
    "    return (len(authorkeys & manualkeys)/len(authorkeys))\n",
    "\n",
    "def substring_match(authorkeys, manualkeys):\n",
    "    c = 0\n",
    "    for ak in authorkeys:\n",
    "        for mk in manualkeys:\n",
    "            c += int(ak.find(mk)!= -1)\n",
    "    \n",
    "    return c/len(authorkeys)\n",
    "    \n",
    "def semantic_match(authorkeys, manualkeys, tokenizer, model):\n",
    "    embdict = dict()\n",
    "    \n",
    "    for k in authorkeys | manualkeys:\n",
    "        inputs = tokenizer.encode_plus(k)\n",
    "        ids = torch.tensor(inputs['input_ids']).unsqueeze(0)\n",
    "        mask = torch.tensor(inputs['attention_mask']).unsqueeze(0)\n",
    "        with torch.no_grad():\n",
    "            embed = model(ids)[0]\n",
    "        #print(embed.shape)\n",
    "        final = torch.mean(embed[:, 1:-1], dim=1).squeeze().detach().numpy()\n",
    "        \n",
    "        embdict[k] = final, np.linalg.norm(final)\n",
    "    \n",
    "    c= 0\n",
    "    for ak in authorkeys:\n",
    "        a = 0\n",
    "        for mk in manualkeys:\n",
    "            iak, imk = embdict[ak], embdict[mk]\n",
    "            a += iak[0].dot(imk[0])/(iak[1]*imk[1])\n",
    "        c += a/len(manualkeys)\n",
    "    \n",
    "    return c/len(authorkeys)\n",
    "    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at allenai/scibert_scivocab_cased were not used when initializing BertModel: ['cls.seq_relationship.bias', 'cls.predictions.transform.dense.bias', 'cls.predictions.transform.LayerNorm.bias', 'cls.predictions.transform.dense.weight', 'cls.predictions.bias', 'cls.predictions.decoder.weight', 'cls.predictions.transform.LayerNorm.weight', 'cls.seq_relationship.weight', 'cls.predictions.decoder.bias']\n",
      "- This IS expected if you are initializing BertModel from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing BertModel from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n"
     ]
    }
   ],
   "source": [
    "import torch\n",
    "import numpy as np\n",
    "from transformers import *\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained('allenai/scibert_scivocab_cased')\n",
    "model = AutoModel.from_pretrained('allenai/scibert_scivocab_cased')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "authorkeys =  {'trastuzumab deruxtecan', 'tucatinib', 'ds8201a', 'her2\\\\xa0+', 'breast cancer', 'third line'} \n",
    "manualkeys = {'from', 'of', 'breast', 'cancer:', 'standard', 'her2-positive', 'third-line', 'no', 'advanced', 'treatment'}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.4891712586085002"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "semantic_match(authorkeys, manualkeys, tokenizer, model)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
